Global Preimplantation Genetic Testing Market Size By Type (Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis), By Application (Maternity Centers & Fertility Clinics, Hospitals), By...

The Global Preimplantation Genetic Testing Market was valued at USD 678.4 million in 2023 and is projected to reach USD 1,362.7 million by 2031, growing at a CAGR of 9.2% during the forecast period of 2023–2031. The market's expansion is driven by the rising incidence of genetic disorders, increasing maternal age, advancements in next-generation sequencing (NGS) technologies, and a growing preference for early disease diagnosis in embryos. Preimplantation genetic testing (PGT) enhances the chances of a successful pregnancy and reduces the risk of inherited genetic diseases, making it an integral part of assisted reproductive technologies (ART).

Drivers:

1. Rising Incidence of Genetic Disorders:

A growing number of couples are opting for PGT to screen for single-gene disorders, chromosomal abnormalities, and inherited diseases like cystic fibrosis and Tay-Sachs disease, thereby increasing demand for these tests globally.

2. Technological Advancements in Genomic Tools:

The evolution of NGS and array comparative genomic hybridization (aCGH) has significantly enhanced test accuracy, turnaround time, and cost-efficiency, further fueling market growth.

3. Increase in Maternal Age and IVF Cycles:

A global trend of delayed pregnancies has increased IVF cycles, boosting the adoption of PGT for screening chromosomal aneuploidies and ensuring healthier outcomes in older patients.

Restraints:

1. Ethical and Legal Challenges:

PGT procedures raise ethical concerns regarding embryo selection and disposal. Varying legal frameworks in different regions also restrict broader market penetration.

2. High Cost of PGT Procedures:

The cost of PGT, often not covered by insurance, poses a barrier, especially in low- and middle-income countries, where affordability remains a key concern.

Opportunity:

1. Emerging Fertility Clinics and ART Centers:

The rapid expansion of fertility clinics, particularly in Asia-Pacific and Latin America, opens significant growth opportunities as these regions adopt advanced reproductive technologies.

2. Integration with AI-Based Embryo Screening:

AI-powered tools in embryo imaging and genetic data interpretation are revolutionizing PGT workflows, offering high accuracy and personalized reproductive care solutions.

Market by System Type Insights:

Preimplantation Genetic Screening (PGS) held the largest market share in 2023. PGS, used primarily to screen embryos for aneuploidies, is widely adopted in IVF clinics to enhance implantation rates and reduce miscarriage risks. However, Preimplantation Genetic Diagnosis (PGD) is gaining traction for identifying specific inherited conditions, indicating robust growth potential.

Market by End-use Insights:

Fertility Clinics accounted for the largest revenue share in 2023, driven by the increasing number of IVF procedures performed globally. The ease of access to specialized equipment and genetic counselors in clinics has made them the preferred facility for PGT. Hospitals and research centers are also showing growing adoption as PGT applications expand into clinical research and genetic disorder studies.

Market by Regional Insights:

North America dominated the global market in 2023, owing to the high adoption of IVF, favorable reimbursement policies, and a well-established healthcare infrastructure. Europe followed closely due to robust governmental support and technological advancements in genetic testing. Meanwhile, Asia-Pacific is expected to witness the fastest growth during the forecast period due to rising fertility awareness, increasing disposable incomes, and growing medical tourism.

Competitive Scenario:

Key players in the Global Preimplantation Genetic Testing Market include:

Illumina, Inc.

Thermo Fisher Scientific Inc.

CooperSurgical, Inc.

Agilent Technologies, Inc.

Natera, Inc.

Invitae Corporation

PerkinElmer, Inc.

Fulgent Genetics

Genomic Prediction, Inc.

Baylor Genetics

These companies are focusing on strategic collaborations, R&D investments, and expanding their global footprint through mergers and acquisitions. For instance:

In 2023, Illumina launched a new AI-integrated sequencing platform designed for higher efficiency in embryo screening.

Natera expanded its portfolio in 2024 with novel PGT-A and PGT-M tests aimed at rare genetic disorders.

CooperSurgical introduced automation-integrated PGT services in its global IVF networks in 2025.

Scope of Work – Global Preimplantation Genetic Testing Market

Report Metric Details

Market Size (2023) USD 678.4 million

Projected Market Size (2031) USD 1,362.7 million

CAGR (2023–2031) 9.2%

Market Segments By System Type (PGS, PGD), By End-use (Fertility Clinics, Hospitals, Research Centers), By Region

Growth Drivers Rising genetic disorders, Technological advancements, Increase in IVF cycles

Opportunities AI-based embryo screening, Expansion in emerging markets

Key Market Developments:

2023: Illumina launched a cloud-based embryo testing analytics platform.

2024: Natera introduced non-invasive preimplantation genetic testing in pilot clinics across the U.S.

2025: CooperSurgical expanded its IVF service network to Southeast Asia, including integrated PGT labs.

FAQs:

1. What is the current market size of the Global Preimplantation Genetic Testing Market?

The market was valued at USD 678.4 million in 2023.

2. What is the major growth driver of the Global Preimplantation Genetic Testing Market?

The key driver is the rising incidence of genetic disorders and increasing maternal age globally.

3. Which is the largest region during the forecast period in the Global Preimplantation Genetic Testing Market?

North America holds the largest share due to robust IVF adoption and healthcare infrastructure.

4. Which segment accounted for the largest market share in the Global Preimplantation Genetic Testing Market?

The Preimplantation Genetic Screening (PGS) segment held the largest market share in 2023.

5. Who are the key market players in the Global Preimplantation Genetic Testing Market?

Leading players include Illumina, Thermo Fisher Scientific, CooperSurgical, Natera, and Agilent Technologies.